Observations contributing to new understanding of bone density and bone strength
| Treatment with different antiresorptive drug classes led to similar vertebral fracture reduction despite different magnitudes of change in bone density.4,5 |
| Early fracture rate improved with risedronate therapy despite no observable bone density changes.6 |
| High and low doses of teriparatide led to similar rates of vertebral fracture reduction but different increases in bone density.7 |
| Large-dose sodium fluoride to treat osteoporosis led to more fractures despite increased bone density.8 |
| A high prevalence of low-impact fractures occurred despite abnormally elevated bone mineral density in 2 patients with autosomal-dominant osteopetrosis.9 |
| Patients with diabetes have increased fracture risk despite normal bone density.10,11 |
| Patients with hyperparathyroidism exhibit discordance between fracture rates and central and peripheral bone density.12 |
| Fracture risk with glucocorticoids is independent of bone mineral density and correlates better with bone microarchitecture measures.13,14 |
| More than half of older women with incident hip fracture did not have a diagnosis of osteoporosis up to 5 years previously.15 |